Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease
<p dir="ltr">Accumulation of advanced glycation endproducts (AGEs) is linked to decline in renal function, particularly in patients with diabetes. Major forms of AGEs in serum are protein-bound AGEs and AGE free adducts. In this study, we assessed levels of AGEs in subjects with and...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513507110682624 |
|---|---|
| author | Naila Rabbani (291722) |
| author2 | Antonysunil Adaikalakoteswari (325054) James R. Larkin (12221192) Sianna Panagiotopoulos (3505712) Richard J. MacIsaac (9718733) Dennis K. Yue (19482394) Gregory R. Fulcher (7774967) Matthew A. Roberts (3056739) Merlin Thomas (6252059) Elif Ekinci (3913966) Paul J. Thornalley (291723) |
| author2_role | author author author author author author author author author author |
| author_facet | Naila Rabbani (291722) Antonysunil Adaikalakoteswari (325054) James R. Larkin (12221192) Sianna Panagiotopoulos (3505712) Richard J. MacIsaac (9718733) Dennis K. Yue (19482394) Gregory R. Fulcher (7774967) Matthew A. Roberts (3056739) Merlin Thomas (6252059) Elif Ekinci (3913966) Paul J. Thornalley (291723) |
| author_role | author |
| dc.creator.none.fl_str_mv | Naila Rabbani (291722) Antonysunil Adaikalakoteswari (325054) James R. Larkin (12221192) Sianna Panagiotopoulos (3505712) Richard J. MacIsaac (9718733) Dennis K. Yue (19482394) Gregory R. Fulcher (7774967) Matthew A. Roberts (3056739) Merlin Thomas (6252059) Elif Ekinci (3913966) Paul J. Thornalley (291723) |
| dc.date.none.fl_str_mv | 2022-12-21T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/ijms24010152 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Analysis_of_Serum_Advanced_Glycation_Endproducts_Reveals_Methylglyoxal-Derived_Advanced_Glycation_MG-H1_Free_Adduct_Is_a_Risk_Marker_in_Non-Diabetic_and_Diabetic_Chronic_Kidney_Disease/26830183 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics chronic kidney disease diabetes glycation methylglyoxal estimated glomerular filtration rate |
| dc.title.none.fl_str_mv | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Accumulation of advanced glycation endproducts (AGEs) is linked to decline in renal function, particularly in patients with diabetes. Major forms of AGEs in serum are protein-bound AGEs and AGE free adducts. In this study, we assessed levels of AGEs in subjects with and without diabetes, with normal renal function and stages 2 to 4 chronic kidney disease (CKD), to identify which AGE has the greatest progressive change with decline in renal function and change in diabetes. We performed a cross-sectional study of patients with stages 2–4 CKD, with and without diabetes, and healthy controls (<i>n </i>= 135). Nine protein-bound and free adduct AGEs were quantified in serum. Most protein-bound AGEs increased moderately through stages 2–4 CKD whereas AGE free adducts increased markedly. Methylglyoxal-derived hydroimidazolone MG-H1 free adduct was the AGE most responsive to CKD status, increasing 8-fold and 30-fold in stage 4 CKD in patients without and with diabetes, respectively. MG-H1 Glomerular filtration flux was increased 5-fold in diabetes, likely reflecting increased methylglyoxal glycation status. We conclude that serum MG-H1 free adduct concentration was strongly related to stage of CKD and increased in diabetes status. Serum MG-H1 free adduct is a candidate AGE risk marker of non-diabetic and diabetic CKD.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Molecular Sciences<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/ijms24010152" target="_blank">https://dx.doi.org/10.3390/ijms24010152</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_68d7950ce8a904eca881046ad4e003e0 |
| identifier_str_mv | 10.3390/ijms24010152 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/26830183 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney DiseaseNaila Rabbani (291722)Antonysunil Adaikalakoteswari (325054)James R. Larkin (12221192)Sianna Panagiotopoulos (3505712)Richard J. MacIsaac (9718733)Dennis K. Yue (19482394)Gregory R. Fulcher (7774967)Matthew A. Roberts (3056739)Merlin Thomas (6252059)Elif Ekinci (3913966)Paul J. Thornalley (291723)Biomedical and clinical sciencesClinical sciencesMedical biochemistry and metabolomicschronic kidney diseasediabetesglycationmethylglyoxalestimated glomerular filtration rate<p dir="ltr">Accumulation of advanced glycation endproducts (AGEs) is linked to decline in renal function, particularly in patients with diabetes. Major forms of AGEs in serum are protein-bound AGEs and AGE free adducts. In this study, we assessed levels of AGEs in subjects with and without diabetes, with normal renal function and stages 2 to 4 chronic kidney disease (CKD), to identify which AGE has the greatest progressive change with decline in renal function and change in diabetes. We performed a cross-sectional study of patients with stages 2–4 CKD, with and without diabetes, and healthy controls (<i>n </i>= 135). Nine protein-bound and free adduct AGEs were quantified in serum. Most protein-bound AGEs increased moderately through stages 2–4 CKD whereas AGE free adducts increased markedly. Methylglyoxal-derived hydroimidazolone MG-H1 free adduct was the AGE most responsive to CKD status, increasing 8-fold and 30-fold in stage 4 CKD in patients without and with diabetes, respectively. MG-H1 Glomerular filtration flux was increased 5-fold in diabetes, likely reflecting increased methylglyoxal glycation status. We conclude that serum MG-H1 free adduct concentration was strongly related to stage of CKD and increased in diabetes status. Serum MG-H1 free adduct is a candidate AGE risk marker of non-diabetic and diabetic CKD.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Molecular Sciences<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/ijms24010152" target="_blank">https://dx.doi.org/10.3390/ijms24010152</a></p>2022-12-21T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/ijms24010152https://figshare.com/articles/journal_contribution/Analysis_of_Serum_Advanced_Glycation_Endproducts_Reveals_Methylglyoxal-Derived_Advanced_Glycation_MG-H1_Free_Adduct_Is_a_Risk_Marker_in_Non-Diabetic_and_Diabetic_Chronic_Kidney_Disease/26830183CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/268301832022-12-21T06:00:00Z |
| spellingShingle | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease Naila Rabbani (291722) Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics chronic kidney disease diabetes glycation methylglyoxal estimated glomerular filtration rate |
| status_str | publishedVersion |
| title | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| title_full | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| title_fullStr | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| title_full_unstemmed | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| title_short | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| title_sort | Analysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease |
| topic | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics chronic kidney disease diabetes glycation methylglyoxal estimated glomerular filtration rate |